|
Título:
|
Noninvasive Assessment of Excessive Erythrocytosis as a Screening Method for Chronic Mountain Sickness at High Altitude
|
|
Autores:
|
Vyas, Kaetan J. ;
Danz, David ;
Gilman, Robert H. ;
Wise, Robert A. ;
Leon-Velarde, Fabiola ;
Miranda, J. Jaime ;
Checkley, William
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
Mary Ann Liebert, 2019-02-06T14:52:35Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Inglés
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
Vyas, Kaetan J., David Danz, Robert H. Gilman, Robert A. Wise, Fabiola Leon-Velarde, J. Jaime Miranda, and William Checkley. Noninvasive assessment of excessive erythrocytosis as a screening method for chronic mountain sickness at high altitude. High Alt Med Biol 16:162-168, 2015.--Globally, over 140 million people are at risk of developing chronic mountain sickness, a common maladaptation to life at high altitude (>2500 meters above sea level). The diagnosis is contingent upon the identification of excessive erythrocytosis (EE). Current best practices to identify EE require a venous blood draw, which is cumbersome for large-scale surveillance. We evaluated two point-of-care biomarkers to screen for EE: noninvasive spot-check tests of total hemoglobin and oxyhemoglobin saturation (Pronto-7, Masimo Corporation). We conducted paired evaluations of total serum hemoglobin from a venous blood draw and noninvasive, spot-check testing of total hemoglobin and oxyhemoglobin saturation with the Pronto-7 in 382 adults aged >/=35 years living in Puno, Peru (3825 meters above sea level). We used the Bland-Altman method to measure agreement between the noninvasive hemoglobin assessment and the gold standard lab hemoglobin analyzer. Mean age was 58.8 years and 47% were male. The Pronto-7 test was unsuccessful in 21 (5%) participants. Limits of agreement between total hemoglobin measured via venous blood draw and the noninvasive, spot-check test ranged from -2.8 g/dL (95%
|
|
En línea:
|
http://doi.org/10.1089/ham.2015.0026
|
